Differentiation-coupled intron retention reveals a candidate NKG2D-TR-like isoform at the murine Klrk1 locus
Abstract
NKG2D (encoded by KLRK1 in humans and Klrk1 in mice) is an activating receptor expressed by cytotoxic lymphocytes. In humans, NKG2D signaling is regulated post-transcriptionally: activated T cells retain intron 4 of KLRK1 to generate NKG2D-TR, a truncated dominant-negative isoform that limits receptor signaling. Whether mice, the principal preclinical model for NKG2D-directed therapies, possess an analogous regulatory mechanism remains unknown. Across four murine RNA-seq datasets comprising 50 samples and spanning T-cell differentiation, graft-versus-host disease, and acute and chronic LCMV infection, we examined the retained-intron isoform Klrk1-203. The transcript retains the canonical start codon, while its predicted stop codon lies within the terminal exon downstream of the final exon-exon junction, suggesting that it may escape nonsense-mediated decay. If translated, Klrk1-203 is predicted to encode a truncated product that retains the cytoplasmic and transmembrane domains but lacks most of the ligand-binding ectodomain. This predicted architecture resembles human NKG2D-TR, although the murine product contains a short C-terminal sequence encoded by the retained intron. Klrk1-203 was below the detection limit in unchallenged naive and early-effector T cells but was induced in differentiated effector and memory populations, reaching approximately one-fifth of total Klrk1 transcripts in one effector-memory sample. Read-level analyses independently demonstrated increased intron 4 retention with differentiation; however, short-read sequencing cannot fully distinguish Klrk1-203 from the co-retained Klrk1-204 transcript, making isoform-specific abundance dependent on model-based quantification. An independent coding-potential algorithm classified Klrk1-203 as non-coding, providing an important counterpoint to the structural predictions. Together, these findings identify Klrk1-203 as a candidate NMD-resistant, differentiation-associated regulator of murine NKG2D and a potential counterpart of human NKG2D-TR that warrants experimental validation.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vivo screening reveals new regulators of Natural Killer cell development and functional response to acute cytomegalovirus infection
Eleanor J. Pring, Simon Clare, … Anneliese O. Speak·bioRxiv·Mar 20, 2026
- Towards understanding of NK cell antigenic specificity
Maria O. Ustiuzhanina, Irina A. Shagina, … Dmitriy M. Chudakov·bioRxiv·Jun 1, 2026
- Regulation of TCR-induced Transcriptional Kinetics by Interleukin 2-inducible T Cell Kinase (ITK) in CD8+ T cells
Josh Hunkins, Zoe K. Bedrosian, … Leslie J. Berg·bioRxiv·Sep 22, 2025
- Expression of a single inhibitory member of the Ly49 receptor family is sufficient to license NK cells for effector functions
Sytse J. Piersma, Shasha Li, … Wayne M. Yokoyama·eLifePeer-reviewed·Sep 26, 2024
- Refined cell transfer model reveals roles for Ascl2 and Cxcr3 in splenic localization of mouse NK cells during virus infection
Laura M. Canaday, Andrew Cox, … Stephen N. Waggoner·The Journal of ImmunologyPeer-reviewed·Jul 22, 2025
- Evidence for prescribed NK cell Ly49 developmental pathways in mice
A. J. Millan, B. A. Hom, … J. O. Manilay·bioRxiv·May 23, 2020